Guangzhou Boji Medical and Biotechnological Co Ltd (300404) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guangzhou Boji Medical and Biotechnological Co Ltd (300404) has a cash flow conversion efficiency ratio of -0.008x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-7.39 Million ≈ $-1.08 Million USD) by net assets (CN¥918.92 Million ≈ $134.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Guangzhou Boji Medical and Biotechnologi (300404) total market value for the company's overall valuation and market capitalisation.
Guangzhou Boji Medical and Biotechnological Co Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Guangzhou Boji Medical and Biotechnological Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Guangzhou Boji Medical and Biotechnological Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangzhou Boji Medical and Biotechnological Co Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Guangzhou Boji Medical and Biotechnologi to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JDM Jingda Mach(Ningbo)Co Ltd
SHG:603088
|
0.077x |
|
AnShan Heavy Duty Mining Machinery Co Ltd
SHE:002667
|
0.106x |
|
Yext Inc
NYSE:YEXT
|
0.055x |
|
Cybrid Technologies Inc
SHG:603212
|
0.041x |
|
D-MARKET Electronic Services & Trading ADR
NASDAQ:HEPS
|
0.043x |
|
Pakuwon Jati Tbk
JK:PWON
|
0.026x |
|
LOGAN GROUP HD -10
F:5LP
|
N/A |
|
Companhia de Saneamento do Paraná - SANEPAR
SA:SAPR3
|
0.045x |
Annual Cash Flow Conversion Efficiency for Guangzhou Boji Medical and Biotechnological Co Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Guangzhou Boji Medical and Biotechnological Co Ltd from 2012 to 2025. View 300404 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.06 Billion ≈ $155.04 Million |
CN¥87.01 Million ≈ $12.73 Million |
0.082x | +207.18% |
| 2024-12-31 | CN¥1.00 Billion ≈ $146.59 Million |
CN¥26.78 Million ≈ $3.92 Million |
0.027x | -27.12% |
| 2023-12-31 | CN¥980.11 Million ≈ $143.42 Million |
CN¥35.95 Million ≈ $5.26 Million |
0.037x | +15.86% |
| 2022-12-31 | CN¥888.72 Million ≈ $130.05 Million |
CN¥28.14 Million ≈ $4.12 Million |
0.032x | -10.97% |
| 2021-12-31 | CN¥846.38 Million ≈ $123.85 Million |
CN¥30.10 Million ≈ $4.40 Million |
0.036x | -82.23% |
| 2020-12-31 | CN¥485.00 Million ≈ $70.97 Million |
CN¥97.07 Million ≈ $14.20 Million |
0.200x | +106199.25% |
| 2019-12-31 | CN¥456.08 Million ≈ $66.74 Million |
CN¥85.87K ≈ $12.57K |
0.000x | -99.71% |
| 2018-12-31 | CN¥423.71 Million ≈ $62.00 Million |
CN¥27.06 Million ≈ $3.96 Million |
0.064x | +0.92% |
| 2017-12-31 | CN¥414.35 Million ≈ $60.63 Million |
CN¥26.22 Million ≈ $3.84 Million |
0.063x | +179.45% |
| 2016-12-31 | CN¥429.84 Million ≈ $62.90 Million |
CN¥-34.24 Million ≈ $-5.01 Million |
-0.080x | -1889.41% |
| 2015-12-31 | CN¥432.68 Million ≈ $63.32 Million |
CN¥1.93 Million ≈ $281.83K |
0.004x | -96.21% |
| 2014-12-31 | CN¥218.48 Million ≈ $31.97 Million |
CN¥25.69 Million ≈ $3.76 Million |
0.118x | -44.43% |
| 2013-12-31 | CN¥205.52 Million ≈ $30.07 Million |
CN¥43.48 Million ≈ $6.36 Million |
0.212x | -12.94% |
| 2012-12-31 | CN¥170.36 Million ≈ $24.93 Million |
CN¥41.40 Million ≈ $6.06 Million |
0.243x | -- |
About Guangzhou Boji Medical and Biotechnological Co Ltd
Boji Medical Technology Co.,Ltd. provides professional contract research services for research and development, and production of drugs and medical devices to pharmaceutical enterprises in China and internationally. The company offers pre-clinical research, clinical research, and other consulting services. It also provides clinical drug production, pilot test scale-up, process verification batch … Read more